<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>stabilization of osteogenic proteins &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/stabilization-of-osteogenic-proteins/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Wed, 23 Sep 2026 01:43:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.1</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>stabilization of osteogenic proteins &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>USP22 Keeps Aging Stem Cells Young by Stabilizing Key Bone-Building Protein</title>
		<link>https://scienmag.com/usp22-keeps-aging-stem-cells-young-by-stabilizing-key-bone-building-protein/</link>
		
		<dc:creator><![CDATA[Beatrice Stafford]]></dc:creator>
		<pubDate>Wed, 23 Sep 2026 01:43:39 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[bone marrow mesenchymal stem cells]]></category>
		<category><![CDATA[Cellular senescence]]></category>
		<category><![CDATA[deubiquitination]]></category>
		<category><![CDATA[impact of aging and inflammation on stem cell health]]></category>
		<category><![CDATA[implications for regenerative medicine and bone healing]]></category>
		<category><![CDATA[molecular mechanisms of stem cell senescence]]></category>
		<category><![CDATA[molecular pathways protecting stem cells from oxidative damage]]></category>
		<category><![CDATA[molecular regulation of BMSC osteogenic potential]]></category>
		<category><![CDATA[NAD+]]></category>
		<category><![CDATA[NAMPT]]></category>
		<category><![CDATA[osteogenic differentiation]]></category>
		<category><![CDATA[osteoporosis]]></category>
		<category><![CDATA[Oxidative stress]]></category>
		<category><![CDATA[oxidative stress in bone marrow mesenchymal stem cells]]></category>
		<category><![CDATA[protein stability]]></category>
		<category><![CDATA[role of reactive oxygen species in bone regeneration]]></category>
		<category><![CDATA[sirtuins]]></category>
		<category><![CDATA[SPI1]]></category>
		<category><![CDATA[stabilization of osteogenic proteins]]></category>
		<category><![CDATA[stem cell aging]]></category>
		<category><![CDATA[strategies to prevent stem cell decline]]></category>
		<category><![CDATA[therapeutic applications of mesenchymal stem cells]]></category>
		<category><![CDATA[USP22]]></category>
		<category><![CDATA[USP22 protein function in stem cell aging]]></category>
		<guid isPermaLink="false">https://scienmag.com/?p=209613</guid>

					<description><![CDATA[New research reveals that the deubiquitinase USP22 protects bone marrow stem cells from oxidative stress-induced senescence by stabilizing the transcription factor SPI1, which boosts NAD+ production and preserves bone-forming capacity.]]></description>
										<content:encoded><![CDATA[<p>Bone marrow mesenchymal stem cells, or BMSCs, are the quiet workhorses of the skeleton. They replenish bone-forming osteoblasts throughout life, and their regenerative power underlies an expanding range of experimental therapies, from grafting cells into fracture sites to engineering scaffolds that coax new bone to grow. Yet these cells have a persistent enemy: oxidative stress. Reactive oxygen species, accumulating through aging, inflammation, metabolic disease or even spaceflight, push BMSCs into senescence, a state in which they stop dividing, lose their osteogenic potential and even secrete inflammatory signals that damage surrounding tissue. When transplanted cells slip into this decline, the therapeutic promise of stem cell medicine collapses with them. A new study published in Molecular Genetics and Genomics now maps a molecular circuit that protects BMSCs from this fate, and its central player is an enzyme better known for its roles in cancer and transcriptional regulation: ubiquitin-specific peptidase 22, or USP22.</p>
<p>The research, led by Min Wu, Yi-Fei Yang and Xiang-Ping Du of the Department of Orthopedics at Jiangxi Provincial Children&#8217;s Hospital in Nanchang, China, began with a simple observation that belied a complex mechanism. When the team exposed BMSCs to hydrogen peroxide, a standard laboratory approach for mimicking oxidative stress, the levels of SPI1, a transcription factor encoded by the Spi-1 proto-oncogene, dropped sharply. The same decline was visible in an animal model: rats whose ovaries had been removed to induce estrogen-deficiency osteoporosis also showed reduced SPI1 in their bone marrow-derived mesenchymal stem cells. The parallel was striking. In both the culture dish and the diseased skeleton, oxidative stress appeared to strip the cells of a factor they apparently needed to stay young.</p>
<p>To test whether that loss mattered, the researchers forced SPI1 expression back up in stressed cells. The effect was dramatic. Overexpressing SPI1 rescued the senescent phenotype that hydrogen peroxide had induced: the cells regained viability, produced fewer reactive oxygen species, and showed reduced staining for senescence-associated beta-galactosidase, a classic enzymatic marker of cellular aging. Just as importantly, SPI1 restoration preserved the cells&#8217; ability to differentiate into bone-forming osteoblasts, which the team quantified using alizarin red S staining of mineralized matrix. In other words, SPI1 was not simply a bystander that declined as cells aged; it appeared to be an active guardian of both youth and bone-building function in the mesenchymal stem cell compartment.</p>
<p>The next question was how SPI1 exerted this protection. Transcription factors work by binding DNA and switching genes on or off, and the researchers had a specific target in mind: NAMPT, the gene encoding nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the NAD+ salvage pathway. NAD+ has become one of the most intensively studied molecules in aging biology, serving as a coenzyme for hundreds of redox reactions and as the fuel consumed by sirtuins, a family of deacylating enzymes that regulate stress resistance, mitochondrial function and longevity. Declining NAD+ levels are a hallmark of aged tissues, and boosting NAMPT activity has previously been shown to rejuvenate senescent mesenchymal stem cells. Through chromatin immunoprecipitation and luciferase reporter assays, the team demonstrated that SPI1 binds directly to the NAMPT promoter and transcriptionally activates it, raising NAD+ levels inside the stressed cells. This elevation of NAD+ was the mechanistic bridge between SPI1 and senescence resistance, connecting a transcription factor to one of aging biology&#8217;s most celebrated metabolic pathways.</p>
<p>But SPI1 is itself a protein, and proteins in the cellular environment are subject to constant quality control. The ubiquitin-proteasome system tags unwanted proteins with chains of ubiquitin molecules, marking them for destruction. For a transcription factor like SPI1, ubiquitination can mean a short half-life and a rapid collapse of expression under stress. This is where USP22 enters the story. USP22 is a deubiquitinating enzyme, a member of a large family of proteases that remove ubiquitin tags and thereby rescue proteins from degradation. The enzyme has attracted growing attention in recent years for its role in stabilizing key regulatory proteins: it has been shown, for example, to deubiquitinate PPARγ in liver cancer cells and FoxM1 in endometrial stromal cells, and to suppress inflammatory signaling by influencing the NLRP3 inflammasome. The Jiangxi team hypothesized that USP22 might perform the same service for SPI1 in BMSCs.</p>
<p>The experimental evidence supported the hypothesis at every step. Co-immunoprecipitation confirmed that USP22 physically interacts with SPI1 inside the cells. Ubiquitination assays then showed that USP22 removes ubiquitin chains from SPI1, and cycloheximide chase experiments, which block new protein synthesis and reveal how fast existing proteins decay, demonstrated that SPI1 protein persists far longer when USP22 is abundant. With SPI1 stabilized, NAMPT transcription stayed high, NAD+ levels were maintained, and the senescence program was held in check. The final piece of the causal puzzle came from a knockdown experiment: when the researchers silenced SPI1 in cells overexpressing USP22, the protective effects of USP22 largely evaporated. Senescence markers rose again, and osteogenic differentiation faltered, showing that SPI1 is the essential downstream mediator of USP22&#8217;s anti-aging action in these cells.</p>
<p>Why does this circuit matter beyond the laboratory? Osteoporosis, which affects hundreds of millions of people worldwide, is fundamentally a disease of failed bone regeneration, in which the balance tips from bone formation to bone resorption. Estrogen deficiency accelerates oxidative stress in the bone marrow, and senescent BMSCs not only fail to produce new osteoblasts but actively worsen the inflammatory milieu. The ovariectomized rat model used in this study reproduces key features of postmenopausal bone loss, and the finding that SPI1 declines in this model suggests that the USP22-SPI1-NAMPT axis may be a plausible therapeutic target. If a drug or gene therapy could raise USP22 activity, or stabilize SPI1 by another means, or simply replenish NAD+ through well-known precursors such as nicotinamide mononucleotide, the senescence cascade in transplanted or endogenous stem cells might be blunted before it begins.</p>
<p>The findings also connect to a much broader scientific conversation about the biology of aging. Cellular senescence was once viewed as a passive consequence of damage accumulation; it is now understood as a tightly regulated program, orchestrated by p53, p21, p16 and chromatin changes, and driven upstream by metabolic deficits such as NAD+ depletion. Sirtuins sit at the junction of metabolism and chromatin, consuming NAD+ as they modify histones and regulatory proteins, which is why the NAD+-sirtuin axis has become a focal point for anti-aging interventions. What this study adds is an upstream control point: a deubiquitinase-transcription factor module that feeds into NAMPT expression and thereby into the entire NAD+ economy of the cell. It suggests that protein stability, not merely gene expression or enzyme activity, may be a decisive lever for keeping stem cells youthful under stress.</p>
<p>There are, of course, important caveats and open questions. USP22 has a complicated double life in the literature: in some contexts it promotes tumor growth and inflammation, and its substrates are numerous and tissue-dependent. Any clinical strategy that elevates USP22 would need to weigh potential oncogenic risks, particularly since SPI1 itself is best known as an oncogene in hematopoietic malignancies, even as the new work assigns it a protective role in mesenchymal stem cells. The current study also relies on cell culture and a rat model; whether the same circuit operates in human bone marrow, and whether it can be safely modulated in patients, remains to be demonstrated. Still, the elegance of the pathway is hard to ignore: oxidative stress degrades SPI1, loss of SPI1 silences NAMPT, silencing of NAMPT drains NAD+, and drained NAD+ leaves stem cells old and bone barren. By inserting USP22 at the top of that cascade, evolution appears to have built a safeguard, and researchers have now found the switch. For an aging global population facing a rising tide of fractures, that switch is worth pulling.</p>
<p><strong>Subject of Research:</strong> How the deubiquitinase USP22 protects bone marrow mesenchymal stem cells from oxidative stress-induced senescence</p>
<p><strong>Article Title:</strong> USP22 alleviates oxidative stress-induced BMSCs senescence by stabilizing SPI1 protein</p>
<p><strong>Article References:</strong> Wu, M., Yang, Y.-F., &amp; Du, X.-P. (2026). USP22 alleviates oxidative stress-induced BMSCs senescence by stabilizing SPI1 protein. <em>Molecular Genetics and Genomics, 301</em>(1), Article 194. <a href="https://doi.org/10.1007/s00438-026-02519-8" rel="noopener noreferrer">https://doi.org/10.1007/s00438-026-02519-8</a></p>
<p><strong>Image Credits:</strong> AI Generated</p>
<p><strong>DOI:</strong> <a href="https://doi.org/10.1007/s00438-026-02519-8" rel="noopener noreferrer">10.1007/s00438-026-02519-8</a></p>
<p><strong>Keywords:</strong> USP22, SPI1, NAMPT, NAD+, bone marrow mesenchymal stem cells, cellular senescence, oxidative stress, deubiquitination, osteoporosis, osteogenic differentiation, sirtuins, protein stability</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">209613</post-id>	</item>
	</channel>
</rss>
